Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

Immuron reported a dramatic rebound in consumer demand with North American Travelan® sales soaring 494% to AUD $0.6 million in FY22 from AUD $0.1 million the prior year. Likewise, global Travelan® and Protectyn® sales surged 431% to AUD $0.9 million, while Australian revenue climbed 318% to AUD $0.3 million as travel resumed post‑pandemic. Growth in the U.S. was largely driven by expanded distribution through Passport Health travel clinics and the Amazon e‑commerce channel, signaling a strong recovery from pandemic lows.

The Market Online: Immuron (ASX:IMC) tables 494pc increase in North American FY22 Travelan sales